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Objective: Myocardial ischemia/reperfusion injury remains a vexing problem. Translating experimental strate-
gies that deliver protective agents before the ischemic insult limits clinical applicability. We targeted 2 proteins in
the nuclear factor-kB pathway, inhibitory kappa B kinase-b, and 26S cardiac proteasome to determine their
cardioprotective effects when delivered during reperfusion.
Methods: C57BL/6 mice underwent left anterior descending artery occlusion for 30 minutes. An inhibitory
kappa B kinase-b inhibitor (Compound A), a proteasome inhibitor (PS-519), or vehicle was administered
at left anterior descending artery release or 2 hours afterward. Infarct size was analyzed 24 hours later. Pres-
sure-volume loops were performed at 72 hours. Serum and left ventricular tissue were collected 1 hour after injury
to examine protein expression by enzyme-linked immunosorbent assay and Western blot.
Results: Inhibitory kappa B kinase-b and proteasome inhibition significantly attenuated infarct size and pre-
served ejection fraction compared with the vehicle groups. When delivered even 2 hours after reperfusion, Com-
pound A, but not PS-519, still decreased infarct size in mice. Finally, when delivered at reperfusion, successful
inhibition of phosphorylated-p65 and decreased interleukin-6 and tumor necrosis factor-a levels occurred in mice
given the inhibitory kappa B kinase-b inhibitor, but not in mice with proteasome inhibition.
Conclusion: Although inhibitory kappa B kinase-b and proteasome inhibition at reperfusion attenuated infarct
size after acute ischemia/reperfusion, only inhibitory kappa B kinase-b inhibition provided cardioprotection
through specific suppression of nuclear factor-kB signaling. This feature of highly targeted nuclear factor-kB in-
hibition might account for its delayed protective effects, providing a clinically relevant option for treating myo-
cardial ischemia/reperfusion associated with unknown periods of ischemia and reperfusion as seen in cardiac
surgery and acute coronary syndromes.Nuclear factor-kappa B (NF-kB) is a transcription factor
that regulates proinflammatory cytokine expression and is
activated in cardiac tissue after ischemia/reperfusion (I/R)
injury.1 Several common cardiovascular drugs that have
nonspecific inhibitory NF-kB activity are a routine part
of our armamentarium, including statins, aspirin, and aden-
osine.2-4 Although strategies aimed at NF-kB inhibition
have been shown to decrease infarct size and preserve
function in animal models of myocardial I/R,5,6 the major-
ity of experimental models study interventions before the
actual ischemic insult. A treatment targeting NF-kB that
is efficacious when delivered before injury may not be
effective or may function differently when administered
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not predictable (ie, patients with acute coronary syndrome).
Furthermore, patients with controlled I/R associated with
cardiac surgery can have disparate ischemic times. The
only physiologic phenomenon clinicians can reproducibly
rely on is reperfusion. Thus, NF-kB inhibition before an is-
chemic insult creates a temporal disconnect between injury
and therapy.7
NF-kB, in its heterodimer form of the p50 and p65 sub-
units, remains inactive in the cell cytoplasm while bound
to the repressor protein, inhibitory kappa-B alpha (IkBa).
After cardiac reperfusion injury, reactive oxygen species un-
leash a kinase cascade that ultimately activates the inhibitory
kappa-B kinase (IKK) complex. In particular, activation of
the IKKb subunit results in phosphorylation of IkBa with
its subsequent polyubiquitination and degradation by the
26S cardiac proteasome. This releases the p65/p50 hetero-
dimer, which translocates to the nucleus and transcribes tar-
get genes, including cytokines and cell adhesion molecules
(Figure 1, A).8
We previously demonstrated that delivery of the protea-
some inhibitor, PS-519, and the IKKb inhibitor, Compound
A, at reperfusion reduced infarct size similar to delivery be-
fore injury.9,10 Yet, the mechanism of cardioprotection re-
mains unclear. These inhibitors have different roles in the
NF-kB pathway. The differences between targeting IKKb,urgery c November 2008




ARC ¼ apoptosis repressor with caspase
recruitment domain
CK-MB ¼ creatine kinase muscle-brain fraction
IkBa ¼ inhibitory kappa-B alpha
IKK ¼ inhibitory kappa-B kinase
IL ¼ interleukin
I/R ¼ ischemia/reperfusion
LAA ¼ left anterior descending
NF-kB ¼ nuclear factor-kappa B
TNF ¼ tumor necrosis factor
a protein specific to the NF-kB pathway11 or the proteasome,
which affects multiple pathways in the cardiomyocyte, may
ultimately alter NF-kB activity after myocardial I/R.
Furthermore, the concept of delayed NF-kB inhibition is
reasonable, because its activation occurs in mammals after
ischemia for up to 4 hours.6,12 Therefore, we investigated
the effect of delayed delivery (at reperfusion or 2 hours after
reperfusion) of these direct and indirect inhibitors in an an-
imal model of myocardial I/R. We proposed that inhibition
of an exclusive NF-kB pathway target, such as IKKb, would
specifically interrupt NF-kB signaling, providing improved
cardioprotection even after late administration.
MATERIALS AND METHODS
Surgical Protocols
All experimental protocols were preapproved by the University of North
Carolina’s Animal Care and Use Committee, and mice received humane
care in compliance with the Guide for the Care and Use of Laboratory An-
imals. C57BL/6 mice 8 to 10 weeks of age were obtained from Charles
River Laboratories (Wilmington, Mass) and housed in Division of Labora-
tory Animal Medicine-approved facilities with light cycling and food and
water access ad libitum at least 7 days before surgery. Our experimental
groups and general protocol are shown in Figure 1, B. With the animals un-
der general anesthesia with ketamine (100 mg/kg) and xylazine (5 mg/kg)
and inhaled isoflurane, myocardial I/R was induced by 30-minute occlusion
of the left anterior descending (LAD) artery using a polyethelene-10 tubing
tied down to the LAD as previously described.10 After 30 minutes of ische-
mia, the tubing was removed. Sham animals had an air knot placed. Imme-
diately after LAD release, the proteasome inhibitor, the IKKb inhibitor, or
a normal saline vehicle was delivered intraperitoneally to the animal. We
measured infarct size in a subset of those animals and in animals given
the inhibitors 2 hours after reperfusion. Infarct size was analyzed 24 hours
after LAD release because gross alterations and irreversible ischemic dam-
age occurs within the first 12 to 24 hours after ischemia.13 To analyze infarct
size 24 hours after LAD occlusion, mice were reanesthetized and hearts
were excised after systemic heparinization. The LAD was ligated at the
same site as the previous occlusion (as noted by the suture that remained af-
ter tubing removal), and the coronary arteries were perfused with fluorescent
polymer microspheres (Duke Scientific, Palo Alto, Calif) to determine the
area at risk. Hearts were then serially sectioned in 1-mm intervals along
the short axis and stained with 1% triphenyltetrazolium chloride to deter-
mine the area of infarct. Image J (National Institutes of Health, Bethesda,
Md) was used to calculate areas of interest.The Journal of Thoracic and CFunctional parameters were obtained 3 days after I/R injury. Mice that
had undergone in vivo I/R and given inhibitors or vehicle at reperfusion
were reanesthetized and a 1F Millar catheter (PVR-1045; Millar Instru-
ments, Houston, Tex) was placed into the left ventricle using a closed chest
technique as previously described.10 In vivo pressure-volume loops were re-
corded with Labview 7.1 software (National Instruments, Austin, Tex) and
interpreted with PVAN (Millar Instruments). We focused on ejection frac-
tion and dP/dt, calculated through PVAN, as measurements of myocardial
function (Figure 1, B).
Reagents
The proteasome inhibitor, PS-519, was dissolved in polypropylene gly-
col before use and delivered at a dose of 1 mg/kg delivered intraperitoneally.
This dose and method of delivery has been shown to decrease proteasome
activity by approximately 80% in murine studies.14,15 Compound A, the
IKKb inhibitor, was dissolved in 10% Cremophor in water and subse-
quently administered at a dose of 5 mg/kg delivered intraperitoneally. Com-
pound A has been shown to have a desirable pharmacokinetic profile,16 and
this dose has been effective in our previous experiments.10
Serum Markers of Injury and Cytokine Expression
A subset of mice were sacrificed 1 hour after LAD release for serum and
left ventricular tissue collection. At this time, approximately 0.4 mL of
blood was collected from animals into serum separator tubes (Becton Dick-
inson, Franklin Lakes, NJ) using the facial vein puncture technique. The
blood was then centrifuged for 10 minutes at 2000g to obtain serum. Serum
creatine kinasemuscle-brain fraction (CK-MB)wasmeasured using aVitros
250 Chemistry System (Ortho-Clinical Diagnostics, Raritan, NJ). Serum
FIGURE 1. A, Diagram of NF-kB activation. Compound A inhibits the
ability of IKKb to phosphorylate IkBa, thus preventing liberation of the
p65/p50 heterodimer. PS-519 acts at the proteasome, preventing polyubi-
quitination and breakdown of phosphorylated IkBa. B, Experiment design.
The inhibitors, Compound A or PS-519, were given at 0 minutes or 2 hours
of reperfusion, with infarct size measured 24 hours later. Separate groups of
animals received the inhibitors at 0 minutes and either sacrificed at 1 hour of
reperfusion for protein analysis or at 3 days for functional analysis. IKK,
Inhibitory kappa-B kinase; CK-MB, creatine kinase muscle-brain fraction;
IL, interleukin; TNF, tumor necrosis factor.ardiovascular Surgery c Volume 136, Number 5 1275
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PTABLE 1. Effects of proteasome and IKKb inhibition on infarct size when delivered at 0 minutes or 2 hours after reperfusion
0 min reperfusion 2 h reperfusion
Sham (n ¼ 4) Vehicle (n ¼ 5) PS-519 (n ¼ 5) Comp A (n ¼ 6) PS-519 (n ¼ 6) Comp A (n ¼ 4)
Infarct : LV (%) 2.3  1.3 45.8  8.2* 24.8  3.8y 25.3  3.8y 31.6  1.5 16.8  1.8y
Infarct : AAR (%) 5.8  3.4 70.4  2.7* 44.6  3.8y 45  10.1y 75.0  2.8 25.9  2.5y
CK-MB (U/L) (n ¼ 4) 9675  608 28500  2050* 12100  4096y 12650  4879y NA NA
LV, Left ventricle; AAR, area at risk; CK-MB, creatine kinase muscle-brain fraction; NA, not available. *P< .05 vs sham. yP< .05 versus vehicle.cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-a were mea-
sured with respective enzyme-linked immunosorbent assay kits (R&D Sys-
tems, Minneapolis, Minn) and quantified with a spectrophotometer (Wallac
1420 VICTOR, PerkinElmer, Waltham, Mass). Concentration of cytokines
was determined according to the respective standard curve and expressed in
picograms/milliliter.
Left Ventricular Protein Expression
Left ventricles obtained 1 hour after LAD release were homogenized in
whole cell lysis buffer (Cell Signaling Technology, Danvers, Mass). Ho-
mogenates were then centrifuged for 30 minutes at 18,000g. The Bradford
assay (Bio-Rad Laboratories, Hercules, Calif) was used to quantify protein
concentration. Western blots were then run on polyvinylidene membranes
as previously described.9 Membranes were incubated with phosphorylated
(phospho) p65 (Ser 536), total endogenous p65 (Sigma-Aldrich, St Louis,
Mo), or GAPDH (Chemicon International, Temecula, Calif) primary anti-
bodies. Visualization of protein bands was performed with an Invitrogen
kit (Invitrogen, Carlsbad, Calif), and densitometry was performed with
Image J software.
Statistical Analysis
Comparisons between experimental infarct groups were made using
1-way analysis of variance with subsequent Dunnett’s test using the
statistical package Prism 4 (GraphPad, San Diego, Calif). Two-tailed
Student t test was used for specific comparisons between other end-
points in the experiment. Data are expressed as mean  standard error
of the mean. Statistical significance was accepted at the 95% confidence
interval.
RESULTS
Temporal Differences in Proteasome and IKKb
Inhibition Affect Reperfusion Injury
Myocardial damage was assessed enzymatically 1 hour
after I/R. Animals that underwent LAD occlusion followed
by vehicle administration had significantly higher levels of
serum CK-MB than sham animals. Compared with the vehi-
cle group, animals that received proteasome inhibition at the
time of reperfusion had significantly lower serum CK-MB
levels. Similarly, IKKb inhibition also resulted in lower
serum CK-MB levels. No significant difference exists
between the PS-519 group and the Compound A group
(Table 1).
When administered at the time of reperfusion, both PS-
519 and Compound A similarly decreased infarct size com-
pared with vehicle-treated mice. Conversely, when PS-519
and Compound A were delivered 2 hours after reperfusion,
only IKKb inhibition significantly reduced infarct size
(Table 1).1276 The Journal of Thoracic and Cardiovascular SMyocardial Function Improves After Delivery of
Proteasome and IKKb Inhibitors at Reperfusion
Pressure-volume loops recorded 3 days after I/R docu-
ment the improvement of cardiac function after administra-
tion of both proteasome and IKKb inhibitors at reperfusion.
Body weight, heart rate, and left ventricular end-diastolic
function were not significantly different among all groups
(data not shown). Loops were shifted to the right in those an-
imals that received vehicle, whereas proteasome and IKKb
inhibition preserved pressure-volume loops close to baseline
(Figure 2, A). After I/R, animals administered vehicle had
significantly lower ejection fraction and dP/dt (Figure 2,
FIGURE 2. Functional assessment of cardiac reperfusion injury. A, Sam-
ple pressure-volume loops from animals administered vehicle, PS-519, or
Compound A at 0 minutes of reperfusion and a baseline animal that had
not undergone surgery. Hemodynamic parameters were measured 3 days af-
ter I/R in 4 groups of mice: baseline (n ¼ 7), vehicle (n ¼ 7), PS-519 (n ¼
7), and Compound A (n ¼ 5). B, Mice treated with proteasome and IKKb
inhibitors at reperfusion had improved function as measured by ejection
fraction; however, proteasome inhibition failed to significantly preserve
dP/dt. *P< .05 versus baseline. **P< .05 versus vehicle.urgery c November 2008
Moss et al Cardiopulmonary Support and PhysiologyFIGURE 3. Myocardial NF-kB activation after reperfusion. Expression of the NF-kB subunit, p65, as well as its activated form, phosphorylated-p65, was
analyzed in left ventricular homogenates 1 hour after treatment at 0 minutes of reperfusion. A mouse administered lipopolysaccharide (LPS), a potent stim-
ulant of NF-kB, is a positive control for p65 phosphorylation. GAPDH serves as a loading control. Densitometrywas performed, and the ratios of phospho-p65
to p65 and phosph-p65 to GAPDH are graphically represented. N¼ 3 for sham, vehicle, PS-519, and Compound A groups. *P<.05 versus sham. **P<.05
versus vehicle. LPS, lipopolysaccharide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.C
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PB) than mice without I/R injury. Proteasome and IKKb inhi-
bition delivered after acute I/R maintained ejection fraction
similar to baseline levels. On analysis of dP/dt, a parameter
that is less load-dependent and more indicative of myocar-
dial contractility than ejection fraction,17 only IKKb inhibi-
tion provided significant functional protection above the
vehicle group. This suggests that although both inhibitors
allow for recovery of global left ventricular function after re-
perfusion, inhibition of IKKb better protects from intrinsic
contractile dysfunction after I/R.
Delayed IKKb Inhibition, but not Proteasome
Inhibition, Decreases Expression of NF-kB
The expression pattern of p65 and phospho-p65, the acti-
vated subunit of the NF-kB heterodimer, was determined inThe Journal of Thoracic and Cheart tissue 1 hour after reperfusion injury. The ratio of
phospho-p65 to both endogenous p65 and GAPDH was
significantly elevated in the animals that received vehicle
at the onset of reperfusion compared with sham animals.
Expression of phospho-p65 was significantly attenuated
in animals treated with the IKKb inhibitor, Compound A.
Proteasome inhibition, however, did not result in decreased
phospho-p65 expression compared with vehicle animals
(Figure 3).
Cytokines Attenuated by IKKb Inhibition, but not
Proteasome Inhibition
Serum cytokines TNF-a and IL-6 in animals that received
vehicle were significantly elevated compared with the sham
group (Figure 4). After administration of Compound A atFIGURE 4. NF-kB–related cytokine expression. Serum cytokines TNF-a (A) and IL-6 (B) in animals treated with PS-519 and Compound A after reperfu-
sion. TNF-a: sham n¼ 3; vehicle n¼ 6; PS-519, Compound A n¼ 4. IL-6: sham, PS-519, Compound A n¼ 4; vehicle n¼ 7. *P<.05 versus sham. **P<
.05 versus vehicle. TNF, Tumor necrosis factor.ardiovascular Surgery c Volume 136, Number 5 1277
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Preperfusion, the levels of TNF-a and IL-6 were significantly
attenuated compared with vehicle. Proteasome inhibition did
not decrease TNF-a, but rather increased it significantly
above sham levels, with a trend suggesting TNF-a levels
were higher than vehicle.
DISCUSSION
When delivered at reperfusion in a murine model of myo-
cardial I/R, both IKKb and proteasome inhibition decrease
infarct size, attenuate CK-MB levels, and preserve ejection
fraction. Our results indicate, however, that the cardiopro-
tective mechanism of delayed proteasome inhibition is inde-
pendent of the NF-kB signaling pathway. Only the specific
IKKb inhibitor prevents phosphorylation of p65 and down-
stream cytokine expression of IL-6 and TNF-awhen admin-
istered at reperfusion. This may contribute to the inability of
PS-519 to reduce infarct size, compared with Compound A,
when delivered 2 hours after LAD release.
This is an important observation in the context of trans-
forming basic science findings into daily clinical practice.
For various cancer models, NF-kB inhibitors, including pro-
teasome inhibitors, have successfully translated from the cell
and animal model to human clinical trials.18 The introduc-
tion of specific NF-kB inhibitors for cardioprotection, how-
ever, has failed to materialize. Matsuki and colleagues19
recently described the cardioprotective effects of fluvastatin
when administered to rats 2 weeks before I/R. However, the
beneficial effects of this statin were lost on delivery at the
time of ischemia or the start of reperfusion. Furthermore,
the mechanism of protection was not mediated via antioxi-
dant properties as expected, but via increased nitric oxide
production. The proteasome inhibitor, like fluvastatin, can
alter several pathways activated after myocardial I/R.
Although PS-519 decreased infarct size in our model of
myocardial I/R when administered after ischemia, the mech-
anism is not NF-kB mediated. Furthermore, any cardiopro-
tective effects of proteasome inhibition were lost after late
delivery 2 hours after myocardial reperfusion. Therapeutic
timing is a critical determinant of mechanism, therefore,
especially regarding relatively nonspecific targets, such as
the cardiac proteasome, that can ultimately modify multiple
cellular mechanisms.
We previously demonstrated that delivery of PS-519 be-
fore myocardial I/R was cardioprotective through inhibition
of NF-kB.6,9 The results of this study demonstrate, however,
that proteasome antagonism immediately after ischemia
does not attenuate phosphorylated-p65 levels or downstream
cytokines regulated by NF-kB. Rather the decrease in myo-
cardial damage at this time point could be mediated through
other proteasome-regulated pathways. Part of the ubiquitin-
proteasome system, the proteasome regulates the proteolysis
and elimination of proteins involved in myriad cellular
mechanisms, from apoptosis and differentiation to inflam-
mation and proliferation.20 For example, destabilization of1278 The Journal of Thoracic and Cardiovascular Suthe apoptosis inhibitor, apoptosis repressor with caspase re-
cruitment domain (ARC), after oxidative stress is mediated
by the ubiquitin-proteasomal pathway.21 Although ARC is
expressed at the start of reperfusion in mouse models of
myocardial I/R, its expression is minimal 2 hours after reper-
fusion.21 Proteasome inhibition at the onset of reperfusion
may prevent the destabilization of ARC, protecting myocar-
dium from reperfusion-induced apoptosis. In fact, ARC-
deficient mice had 50% larger infarcts after myocardial I/R
than their wild-type controls.22 In addition to altering apo-
ptotic pathways, proteasome inhibition has also been shown
to induce heat-shock proteins in cardiomyocytes, conferring
protection after oxidative stress.23,24 Thus the effects of
proteasome inhibition can be multifactorial and are not
restricted to the NF-kB pathway alone.
Unlike the proteasome, IKKb is specific to the NF-kB
pathway. IKKb knockout mice die in utero of liver failure
from massive hepatocyte apoptosis and have complete dis-
ruption of the NF-kB signaling pathway.25 Pharmacologic
inhibition of IKKb with Compound A is a specific process
that directly prevents the phosphorylation of the NF-kB re-
pressor protein, IkBa. Downstream expression of phosphor-
ylated p65 and cytokines IL-6 and TNF-a is repressed after
administration of Compound A. This pattern of NF-kB dis-
ruption is similar when IKKb is inhibited before10 and after
the period of cardiac ischemia. Furthermore, IKKb inhibi-
tion appears to be even more effective after 2 hours of reper-
fusion. Late protection is rational, because previous studies
have documented the persistence of NF-kB levels for several
hours after reperfusion.26,27 Although this smaller infarct
size is not significantly different from delivery at reperfu-
sion, this trend emphasizes the distinct advantage specific
NF-kB inhibition through the IKKb subunit provides in
a late setting compared with the relatively nonspecific
proteasome.
CONCLUSIONS
Despite 3 decades of research investigating methods to re-
duce myocardial reperfusion injury, few experimental thera-
pies have translated successfully to our patients. Although
hundreds of pharmacologic inhibitors have been tested in
animal models of I/R, our review reveals a dearth of studies
that have focused on delayed interventional therapies for
cardiac reperfusion injury. To our knowledge, this is the first
study both directly comparing 2 applicable NF-kB inhibitors
and investigating delayed delivery of NF-kB inhibition after
the reperfusion event has occurred. This approach is espe-
cially important, because successful NF-kB–mediated cardi-
oprotection is not only temporally dependent but also
dependent on the specificity of the mechanism of NF-kB
inhibition.
The authors thank Peter Charles, PhD, for statistical assistance
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DISCUSSION
Dr Frank Sellke (Boston, Mass). That was a nice study.
My question is kind of generic. You mentioned in the begin-
ning of your talk that there have been approximately 10,000
studies showing benefit in laboratory animals, yet when it
goes to the clinic, very few, if any, really show any promise.
Why is that?
DrMoss.Well, I think there are many factors. One is tim-
ing. It is really surprising, but actually when you start read-
ing all of those studies, you will find that the majority of
inhibitors are given before ischemia or during ischemia,
a time for us that isn’t clinically relevant. You can’t really
pinpoint what is going to happen during that time, and the
time of reperfusion, when the stent is placed or when you
come off clamp, is the one thing that we do know. Unfortu-
nately, temporally relevant conditions haven’t really been
studied that much, and so that was one of the points of this
article. It is almost more conceptual, I think. The point of
this article is that we really need to pin down exactly what
we are translating into clinical practice, because it may not
work if you do it a different way in those animal studies.
Then also, for example, one limitation of this study is that
these are healthy 8-week-old C57 black six mice. These
aren’t knockout or like apolipoprotein E, and they develop
atherosclerosis like you might find in the person undergoing
CABG. They are not obese or diabetic. I think we need to
have more studies that look at a multifactorial animal, be-
cause it may not work. Although it might work in a healthy
animal, it may not work in one that is diabetic or has other
comorbidities.ardiovascular Surgery c Volume 136, Number 5 1279
